Podcasts about 3B

Welcome to Omni Talk's Retail Daily Minute, sponsored by RetailClub and Mirakl. In today's Retail Daily Minute:Nintendo exits Amazon's U.S. storefront amid a third-party seller dispute, skipping the Switch 2 launch and leaving American shoppers out of the release.France clamps down on ultra-fast fashion, introducing new legislation aimed at Shein and Temu to address sustainability and labor concerns.Home Depot strikes a $4.3B deal to acquire GMS, expanding its contractor-focused business through its SRS Distribution arm as it doubles down on the Pro segment.The Retail Daily Minute has been rocketing up the Feedspot charts, so stay informed with Omni Talk's Retail Daily Minute, your source for the latest and most important retail insights. Be careful out there!

Reading by Pastor Teressa Wiley ---   1 Kings 22; 2 Chronicles 18   https://www.biblegateway.com/passage/?search=1%20Kings%2022%3B%202%20Chronicles%2018&version=ESV&interface=print

In this week's Fast Five Podcast, sponsored by the A&M Consumer and Retail Group, Simbe, Mirakl, Ocampo Capital, Infios, and ClearDemand, we deep dive into Whatnot, the live streaming shopping app that hit $3B in sales selling trading cards, sneakers, and collectibles. We explore whether this QVC-meets-Twitch model can expand beyond niche markets and why video commerce is finally taking off in America. Timestamps: 8:28 - What is Whatnot? 9:47 - US vs China video commerce 10:44 - Niche vs mass market potential 13:05 - eBay 2.0 comparison 14:30 - Platform distribution challenges Catch the full episode here: https://youtu.be/3lsaTBvBuMs #Whatnot #LiveShopping #VideoCommerce #CollectiblesTrading #SocialCommerce #LiveStreaming

Stephen Petasky is the founder and CEO of The Luxus Group, a hospitality and development firm specializing in luxury vacation homes, global restorations, and high-end resort communities. Over nearly two decades, he's raised more than $100 million, facilitated 20,000 vacations, and partnered with brands like Four Seasons to deliver premium lifestyle experiences through real estate. His business journey spans from fractional home ownership to international development, all driven by a passion for design, family travel, and scalability.     Make sure to download our free guide, 7 Questions Every Passive Investor Should Ask, here. Key Takeaways Stephen started Luxus by solving his own problem—traveling with young kids—and turned that into a $100M global vacation home portfolio. Raising capital gets easier when the investment includes a dual purpose, like lifestyle use alongside financial return. Scaling a business requires building it “back to front”—start with the exit goal, then reverse engineer every step. Real estate and development success takes patience; some ventures took 7–10+ years to turn profitable. Subject matter expertise becomes a valuable asset after years of refinement, leading to higher-impact, lower-risk projects.     Topics How a Personal Travel Need Became a Syndicated Real Estate Venture Started Luxus to create a family-friendly alternative to hotels or inconsistent vacation rentals. Solved the problem of predictability, comfort, and flexibility by imagining ownership of 30 homes—then invited others to co-invest. Raised $3.5M to purchase three homes; word-of-mouth demand led to $100M+ raised and 50 properties acquired. Dual-Purpose Investing: Lifestyle + Returns Investors received lifestyle benefits—discounted nightly rates—alongside capital preservation. These vacation privileges created real financial savings, boosting total return beyond simple IRR metrics. Stephen compares the model to a “golf club that sells at the end”—with liquidity and upside built in. How to Make Raising Capital Easier Dual-purpose investments or vendor-aligned capital (e.g., landowners or contractors investing) make raises more compelling. Giving investors experiential or operational upside increases buy-in—even when the financial returns are moderate. Partnerships built on aligned interests are more resilient over time. Scaling With Clarity and Hindsight Luxus' new business model was built “back to front,” starting with a $100M valuation target and working backward to day one. Planning for bottlenecks—legal, financial, tech, or operational—can reduce future breakdowns. AI tools now help model scalable pathways and highlight structural weak points before launch. New Ventures: Management, Development, and Restorations Luxus now manages luxury short-term rentals it doesn't own, applying hotel-like service and strategy. Stephen is a core partner in the Four Seasons Private Residences Las Vegas ($1.3B sellout). The company also restores centuries-old Tuscan estates for North American and European clients—12 years in, with a waitlist.    

In this episode of Abundance Thursdays, Vinney Smile Chopra and Gualter Amarelo tackle the real reason most businesses stall out—team structure. Vinney, a real estate legend who's raised over $220 million and owns $1.3B in assets, reveals his top 10 hacks for building a team that scales your business, boosts investor trust, and fuels sustainable growth.   Here's what you'll learn:

Reading by Karen Griffin ---   1 Kings 16; 2 Chronicles 17   https://www.biblegateway.com/passage/?search=1%20Kings%2016%3B%202%20Chronicles%2017&version=ESV&interface=print

Last week, Guild Mortgage made headlines with its $1.3 billion acquisition by Bayview Asset Management. This week, Diego welcomes Terry Schmidt, the CEO of Guild Mortgage, to talk about how Guild plans to innovate, scale and deepen customer loyalty, without losing its retail identity. Terry and Diego dive into the synergy between Guild's distributed retail model and Bayview's $700 billion servicing portfolio. They also talk about Guild's investment in AI and tech, ongoing M&A ambitions, and how cultural alignment and local relationships will still be their secret weapon. Here's what you'll learn: Why Bayview's acquisition of Guild was a strategic move, not just financial. Guild's "customers for life" strategy delivers strong recapture performance. How Bayview's capital unlocks new proprietary loan products for Guild. Cultural alignment is central to Guild's M&A and growth strategy. AI and tech will play a major role in Guild's next chapter. Related to this episode:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Guild Mortgage Bayview to buy Guild for $1.3B in cash, taking lender private | HousingWire Terry Schmidt  | LinkedIn ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠HousingWire | YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Enjoy the episode! The Power House podcast brings the biggest names in housing to answer hard-hitting questions about industry trends, operational and growth strategy, and leadership. Join HousingWire president Diego Sanchez every Thursday morning for candid conversations with industry leaders to learn how they're differentiating themselves from the competition. Hosted and produced by the HousingWire Content Studio. Learn more about your ad choices. Visit megaphone.fm/adchoices

This week, we have some updates on Trump's appeal in the E. Jean case and the case against Alex Jones brought by the families of the Sandy Hook massacre. Trump pardons are costing American taxpayers over $1.3B. The DoJ is asking for life in prison for Edward Kelley for the January 6th insurrectionist's FBI murder plot. Plus, we have some comings and goings, and a little more on the Proud Boys' lawyer Augustus Sol Invictus.Thank you, CB Distillery.Use promo code CLEANUP at CBDistillery.com for 25% off your purchase.Specific product availability depends on individual state regulations.  Allison Gillhttps://muellershewrote.substack.com/https://bsky.app/profile/muellershewrote.comHarry DunnHarry Dunn | Substack@libradunn1.bsky.social on BlueskyWant to support this podcast and get it ad-free and early?Go to: https://www.patreon.com/aisle45podTell us about yourself and what you like about the show - http://survey.podtrac.com/start-survey.aspx?pubid=BffJOlI7qQcF&ver=short

Reading by Pastor Teressa Wiley ---   1 Kings 15; 2 Chronicles 13-16   https://www.biblegateway.com/passage/?search=1%20Kings%2015%3B%202%20Chronicles%2013-16&version=ESV&interface=print

According to Bloomberg reporting, Meta Platforms (META) discussed a possible acquisition of video startup Runway as the company seeks to expand its presence in the tech space. Jenny Horne looks at META's continued push into AI as Mark Zuckerberg's company recently completed its $14.3B investment in Scale AI. Jenny also shares Citi's price target hike to $803 from $690. Later, she cites NHTSA reports that it will be probing videos of Tesla's (TSLA) Robotaxi debut.======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Dr. Shaalan Beg and Dr. Kristen Ciombor discuss practice-changing studies in GI cancers and other novel treatment approaches that were presented at the 2025 ASCO Annual Meeting. Transcript Dr. Shaalan Beg: Hello, I'm Dr. Shaalan Beg, welcoming you to the ASCO Daily News Podcast. I'm a medical oncologist and an adjunct associate professor at UT Southwestern Medical Center in Dallas, Texas. There were some remarkable advances in gastrointestinal cancers that were presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Kristen Ciombor to discuss some exciting GI data. Dr. Ciombor is the Ingram Associate Professor of Cancer Research and a co-leader of Translational Research and the Interventional Oncology Research Program at the Vanderbilt Ingram Cancer Center. Our full disclosures are available in the transcript of this episode. Dr. Ciombor, it's great to have you on the podcast today. Dr. Kristen Ciombor: Thanks, Dr Beg. It's great to be here. Dr. Shaalan Beg: Alright, let's kick it off. Big year for GI cancers. We'll start off with LBA1. This was the ATOMIC study sponsored by NCI and the National Clinical Trials Network (NCTN) and the Alliance group. This is a randomized study of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for stage III mismatch repair deficient colorectal cancer. Dr. Kristen Ciombor: I think this study was really definitely practice-changing, as you can tell because it was a Plenary. But I do have some concerns in terms of how we're actually going to implement this and whether this is the final answer in this disease subtype. So, as you said, the patients were enrolled with stage III resected mismatch repair deficient colon cancer, and then they were randomized to either modified FOLFOX6 with or without atezolizumab. And that's where it starts to become interesting because not many of us give FOLFOX for 6 months like was done in this study. Obviously, the study was done over many years, so that was part of that answer, but also the patients received atezolizumab for a total of 12 months. So the question, I think, that comes from this abstract is, is this practical and is this the final answer? I do think that this is practice-changing, and I will be talking to my patients with resected mismatch repair deficient colon cancer about FOLFOX plus atezolizumab. I think the big question is, do these patients need chemotherapy? And can we do a neoadjuvant approach instead? And that's where we don't have all the answers yet. Dr. Shaalan Beg: Yeah, but it has been great to see immunotherapy make its way into the adjuvant space after having made such a big impact in the metastatic space, but still some unanswered questions in terms of the need for chemotherapy and then the duration of therapy, which I guess we'll have to stay tuned in for the next couple of years to to get a lot of those questions answered. Dr. Kristen Ciombor: Yeah, but a big congratulations to the study team, to the NCTN, the NCI. I mean, this is really a great example of federally funded research that needs to continue. So, great job by the study team. The DFS 10% difference is really very large and certainly a practice-changing study. Dr. Shaalan Beg: Yeah, and and sticking with colon cancer, and and this another federally funded study, but this time funded by a Canadian cancer clinical trials group was LBA3510. This is the CHALLENGE study. It's a randomized phase 3 trial of the impact of a structured exercise program on disease-free survival for stage III or high-risk stage II colon cancer. This study got a lot of buzz, a lot of mainstream press coverage, and a lot of discussions on what that means for us for the patients who we're going to be seeing next week in our clinic. What was your takeaway? Dr. Kristen Ciombor: Yeah, this is a really interesting study, and I was so glad to see it presented because this partially answers one of the questions that patients always have for us in clinic, right? You know, once they've completed their standard chemotherapy and surgery, what else can they do to help prevent recurrence? And so we've always known and sort of extrapolated that healthy lifestyle habits are good, but now we have data, particularly in these patients. Most of them were stage III colon cancer patients, those had high-risk stage II cancer. And basically, the goal was to increase their physical activity by at least 10 MET hours per week. So, my big question, of course, as I came into this presentation was, “Okay, what does that mean exactly? How does that translate to real life?” And really what the author presented and explained was that basically most patients could hit their target by adding a 45- to 60-minute brisk walk 3 to 4 times a week. So I think this is very approachable.  Now, in the confines of the study, this was a structured exercise program, so it wasn't just patients doing this on their own. But I do think kind of extrapolating from that, that this is very achievable for most patients. And not only did this prevent recurrence of their prior cancer, but actually the rate of new primary cancer diagnoses, was less, which is really interesting, especially in the breast and prostate cancer. So this was a really interesting, and I think practice-changing study as well, especially given that this is something that most patients can do. Dr. Shaalan Beg: Yeah, and there was a lot of discussion in the hallways after the presentation in terms of how this really changes our existing practice because most folks already recommend exercise as a way for improving outcomes in cancer patients. So we've already been doing that. Now we have some data on how much it can impact the benefit. But there was some discussion about what the actual degree of impact was. There was a drop-off rate in terms of how long folks were able to stick with this exercise regimen. But you've seen this in clinic when someone have their surgery, they have their chemotherapy, they've been so intimately involved with the oncology world, with the oncology practice, and they somehow feel that they're being let loose into this mean, angry world without any guidance and they're looking for something to do. “What more can I do in terms of my lifestyle?” And then here we have very solid data, as solid as can be for an intervention like exercise, showing that there is an impact and you can give a prescription for exercise when someone wraps up their chemotherapy for colon cancer, thanks to the study. Dr. Kristen Ciombor: Yeah. It was a great study. Dr. Shaalan Beg: Moving to gastroesophageal cancer, another late-breaking abstract. This is LBA5. The MATTERHORN trial was a phase 3 trial of durvalumab plus FLOT for resectable GE junction and gastric cancer. And again, another area where immunotherapy has made an impact, and here we're seeing it move closer for earlier-stage disease. What was your take-home for the MATTERHORN trial? Dr. Kristen Ciombor: Yeah, so this study looked at neoadjuvant perioperative durvalumab plus our current standard chemotherapy of FLOT versus placebo plus FLOT. And this was a large study, almost 1,000 patients were randomized. And the primary endpoint was event-free survival, and it was definitely met in favor of the D + FLOT arm, as Dr. Klempner discussed after Dr Janjigian's presentation. I do think there are still some unanswered questions here. Overall survival is not yet mature, so we do have to wait and see how that shakes out. But it's very interesting and kind of is reflective of what, as you said, we're looking at earlier and earlier lines of therapy, particularly with immunotherapy, in these GI cancer spaces. So it makes a lot of sense to test this and and to look at this. So the toxicity was pretty similar to what we would expect. Primary endpoint was met, but again, we'll have to wait and see what the survival data looks like. Dr. Shaalan Beg: Yeah, and in oncology, we know, especially for treatment that does add additional cost, it does add additional potential toxicity that we want to see that overall survival nudged. I did see some polls on social media asking folks whether their practices changed from this, and I think the results were favoring adding durvalumab for this group of patients but understanding that there are caveats to the addition of treatments and the eventual FDA approval in that indication as well. Dr. Kristen Ciombor: Exactly. I completely agree with that. Dr. Shaalan Beg: All right. How about we stick with gastroesophageal cancer? LBA4002 was trastuzumab deruxtecan versus ramucirumab plus paclitaxel for second-line treatment in HER2-positive unresectable or metastatic gastric cancer or GE junction cancer. This was the DESTINY-Gastric04 study. And again, antibody-drug conjugates making a big impact across different diseases. And here we have more data in the HER2-positive gastric cancer space. Your thoughts on this study? Dr. Kristen Ciombor: Yeah, so this is a really important space in gastroesophageal cancer because the HER2 positivity rate is fairly high as compared to some of our other tumor types. So, I do think one of the important things was that patients did have biopsy confirmation of HER2 status, which was very important, and then they were randomized to either T-DXd versus the kind of second-line standard of ramucirumab-paclitaxel. So this was a great practical study and really answers a question that we had for a while in terms of does anti-HER2 therapy in the second-line really impact and improve survival. So we did see a statistically significant improvement favoring T-DXd. I do think it's always important to look at toxicity, though, too. And there was about almost 14% rate of interstitial lung disease, which of course is the most feared toxicity from some of these antibody-drug conjugates, especially T-DXd. So I do think it's important to keep that in mind, but this is definitely a great addition to the armamentarium for these HER2-positive patients. Dr. Shaalan Beg: And pancreas cancer was on the stage after a very long time with a positive clinical trial. This is Abstract 4006. These were preliminary results from a phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel alone for previously untreated metastatic pancreas cancer. This is a frontline clinical trial of gemcitabine/nab-paclitaxel plus/minus the study drug. There were other cohorts in this study as well, but they reported the results of their part 3B arm. And great to see some activity in the pancreas space. And your thoughts? Dr. Kristen Ciombor: Yeah, we definitely need better treatments in pancreas cancer. This was a very welcome presentation to see. The elraglusib is an inhibitor of GSK-3beta, and it's thought that that mediates drug resistance and EMT. And so this is, I think, a perfect setting to test this drug. So patients basically were randomized. Patients with metastatic pancreas cancer were randomized 2: 1 to gemcitabine/nab-paclitaxel plus or minus this elraglusib. So, what we saw was that overall survival was better with the addition of this new drug. And overall, not only the 1-year overall survival, but also median overall survival.  The thing that was interesting, though, was that we saw that the overall survival rates were 9.3 months with the combination versus 7.2 months with just gemcitabine/nab-paclitaxel. And that's a little bit lower than we've seen in other studies. So, not sure what was going on there. Was it the patients that were a bit sicker? Was it a patient selection, you know, thing? I'm not really sure how to explain that so much. Also, the toxicity profile was much higher in terms of visual impairment, with over 60% of patients being treated with the combination versus 9% with gemcitabine/nab-paclitaxel. So these were mild, grade 1 and 2, but still something to be cautious about. Dr. Shaalan Beg: And especially with this being a phase 2 trial, making sure that in a larger study we're able to better evaluate the toxicity and see if the control arm in the larger confirmatory study performs differently will be really important before this compound makes it to the clinic in our space. But very exciting to see these kinds of results for pancreas adenocarcinoma. Dr. Kristen Ciombor: Yeah. Dr. Shaalan Beg: We've talked, it seems, a couple of times on this podcast about the BREAKWATER clinical trial. We did hear PFS and updated OS data, updated overall survival data on first-line encorafenib plus cetuximab plus modified FOLFOX6 for BRAF-mutated colorectal cancer. This was LBA3500. And eagerly anticipated results – we have all previously heard the progression-free survival results – but here we heard updated overall survival results, and very well-received study it seemed from the audience that time. So what are your takeaways on the updated results for BREAKWATER? Dr. Kristen Ciombor: In my opinion, this was one of the most practice-confirming studies. As you mentioned, we've already seen some of the preliminary data of BREAKWATER at prior meetings. But really what was particularly impactful for me was the median overall survival with the BREAKWATER regimen. So, again, patients received FOLFOX, encorafenib cetuximab in the first line if they had BRAF-mutated V600E-mutated colorectal cancer. And the median PFS was 12.8 months, which was actually really remarkable in this traditionally very aggressive, poor prognosis subtype of tumors. So, by seeing a median overall survival of 30.3 months was just incredible, in my opinion. Just a few years ago, that was considered the median overall survival for all comers for metastatic colorectal cancer. And we know the median overall survival was more in the less than 12 months range for BRAF. So this was incredibly impactful, and I think should be absolutely practice-changing for anyone who is eligible for this regimen.  I think again, where the practice meets the study is what's kind of important to think about too, how long did patients get FOLFOX, and certainly it adds toxicity to add a BRAF-targeted regimen on top of FOLFOX already. So, one of the other interesting things about the study, though, was that even though it didn't complete treatment, they actually did look at encorafenib/cetuximab alone and in the first line without chemotherapy. And those preliminary results actually looked okay, especially for patients who might not be able to tolerate chemotherapy, which we certainly see in practice. So, overall, definitely more data. And I agree that it's certainly practice-changing. Dr. Shaalan Beg: And it completely, as you mentioned, changes the outlook for a person who's diagnosed with BRAF-mutated metastatic colon cancer today versus even 7 or 8 years ago. Dr. Kristen Ciombor: And we're seeing this over and over in other subtypes too, but how you choose to treat the patient up front really matters. So really giving the right regimen up front is the key here. Dr. Shaalan Beg: And along the same lines, Abstract 3501 wanted to answer the question on whether people with MSI-high metastatic colorectal cancer need double checkpoint inhibitor therapy or is single therapy enough. So this [CheckMate-8HW] study compared nivo plus ipi with nivo alone, nivo monotherapy for MSI-high metastatic colorectal cancer. And we've known that both of these are fairly active regimens, but we also know the chance of immune-related adverse events is significantly higher with combination therapy. So this was a much-needed study for this group of patients. And what were your takeaways here? Dr. Kristen Ciombor: This, of course, has been really nivo-ipi in the first-line MSI-high metastatic colorectal cancer is now a standard of care. And not everybody is eligible for it, and there could be reasons, toxicity reasons, and other things too. But as we've been seeing for the last couple of years, immunotherapy clearly beats chemo in this space. And now looking at doublet versus single immunotherapy treatment in the first line, I think really nivo-ipi does beat out monotherapy. I will say, however, there is a caveat in that we still haven't seen the nivo-ipi versus nivo in the first line. So what has been presented thus far has been across all lines of therapy, and that does muddy the waters a little bit. So definitely looking forward and and we've asked this many times and based on the statistical plan and and what not, you know, we just haven't seen that data yet. But I do think it's becoming increasingly important to consider doublet immunotherapy for these patients as long as there are no contraindications. With the again, with the caveat that we have to have these toxicity discussions in the clinic with patients because many patients can tolerate it, you know, this regimen fairly well, but there can be very severe toxicities. So, I think an informed discussion should really be had with each patient before moving forward. Dr. Shaalan Beg: Yeah, informed decision, making them aware of the potential of real significant toxicities, immune-related toxicities with double therapy. But I am curious in your practice, how often do you see people choosing doublet therapy as frontline? Dr. Kristen Ciombor: So patients are really savvy, and a lot of times they've heard this data before or have come across it in patient advocacy groups and other things, and it's really nice to be able to have that conversation of the risk versus benefit. So I will say not all of my patients choose doublet, and many of them are still cured with immunotherapy monotherapy. So the big question there is, will we ever understand who actually needs the doublet versus who can still be cured or have very good long-term outcomes with just the single agent? And that has not been answered yet. Dr. Shaalan Beg: What a great point. So the last abstract I was hoping we could talk about is POD1UM-303 or the INTERAACT2 subgroup analysis and impact of delayed retifanlimab treatment for patients with squamous cell carcinoma of the anal canal. What were your thoughts here? Dr. Kristen Ciombor: This was a study, actually we saw at ESMO, we saw the primary data at ESMO last year, and this was an update with some exploratory analyses. But this was really an important study because once again, we're looking at immunotherapy in later lines of therapy. That's how we started looking at and investigating immunotherapy, and now we're moving it up and up in the treatment course. So this was a study of carboplatin/paclitaxel plus or minus retifanlimab. Actually it was retifanlimab versus placebo. And it was a positive study, as we heard last year. This actually led to FDA approval of this regimen last month, just before ASCO, and it has now been incorporated in the NCCN guidelines as the preferred first-line option.  So what I thought was important from the additional data presented at ASCO was looking at the different subgroups, it did not appear that patients with liver mets or not had different outcomes. So that was really good to see because sometimes in colon cancer we see that immunotherapy doesn't work as well when patients have liver mets. And interestingly, because we use immunotherapy in anal cancer without any biomarkers, unlike with colon cancer or some of the other tumor types, also the authors looked at PD-L1 status, and it did look like maybe patients did a little bit better if they had higher PD-L1 expression, but patients still could benefit even if they were PD-L1 negative. So that was important, I think, and we will continue to see further data come out from this study. I want to mention also that EA2176 just completed accrual, so that was carbo-taxol plus or minus nivolumab. And so we should be seeing that data sometime soon, which will hopefully also confirm the ongoing role for immunotherapy in the first-line setting for anal cancer. Dr. Shaalan Beg: That was a fantastic review. Thank you, Dr Ciombor. Thanks for sharing your valuable insights with us today on the ASCO Daily News Podcast. Dr. Kristen Ciombor: Thanks for having me here. Dr. Shaalan Beg: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode. And if you value the insights that you hear on the podcast, please take a moment to rate, review, and subscribe, wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Shaalan Beg  @ShaalanBeg  Dr. Kristen Ciombor @KristenCiombor Follow ASCO on social media:    @ASCO on Twitter   @ASCO on BlueSky  ASCO on Facebook    ASCO on LinkedIn    Disclosures:   Dr. Shaalan Beg:   Consulting or Advisory Role: Ipsen, Cancer Commons, Foundation Medicine, Science37, Nant Health, Lindus Health Speakers' Bureau: Sirtex Research Funding (Inst.): Delfi Diagnostics, Universal Diagnostics, Freenome Dr. Kristen Ciombor: Consulting or Advisory Role: Pfizer, Incyte, Exelixis, Bayer, ALX Oncology, Tempus, Agenus, Taiho Oncology, Merck, BeiGene Research Funding (Inst.): Pfizer, Boston Biomedical, MedImmune, Onyx, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Novartis, Incyte, Amgen, Sanofi, Bristol-Myers Squibb, Array BioPharma, Incyte, Daiichi Sankyo, Nucana, Abbvie, Merck, Pfizer/Calthera, Genentech, Seagen, Syndax Travel, Accommodations, Expenses: Incyte, Tempus

Jared Wyllys, from CHGO, joins Jeremy & Pat this week. Tough week for the Cubs. We discuss the roster challenges at 3B, starting rotation, and the bullpen.  We look ahead to another tough stretch. We close the show with a profile of former Cub Luis Valbuena.  Enjoy....and Go Cubs!

987: Kelly Services is transforming the way enterprises approach staffing through AI-powered innovation, scalable tech, and smart acquisitions. In this episode of Technovation, Peter High speaks with Sean Perry, Chief Information Officer of Kelly Services, a $4.3B staffing and professional services company. Sean shares how he's driving modernization across IT, integrating recent acquisitions like Motion Recruitment, and developing innovative AI tools to deliver enterprise-wide value. From launching a custom AI assistant (GRACE) to implementing a modern tech stack across legacy systems, Sean reveals how Kelly is reshaping its digital future while improving candidate and client experiences. He also draws lessons from his time at Amazon and Robert Half to rethink internal products with a customer-first mindset.

In Episode 101 of Chase for 28, Chris and the Podcast Padre return with a heavy dose of Yankee frustration and food-for-thought—literally. After enduring the Yankees' slump (including a brutal seven-game skid), they break down recent performances, share their firsthand experience from a night at the Audi Club, and vent about Anthony Volpe's inconsistency at the plate and in the field.This episode isn't just rants and raves—it's stats-backed. The duo dives deep into Volpe's numbers, Domínguez's uneven production, the potential long-term plan for Cody Bellinger at first base, and whether Aaron Judge might ever pull a Mickey Mantle and switch positions. Add in listener shoutouts, trivia, and a nostalgic look at Yankee greats, and it's another packed edition of Chase for 28.Key Topics Covered:Yankees' record: 45-32 (2-game lead in AL East)Recap: Sweeps by Boston and Angels, bounce-back vs. OriolesInside the Yankees Audi Club: Atmosphere vs. AffordabilityAnthony Volpe's ongoing struggles: high K-rate, low impactMartian, Bellinger, and the outfield logjamPaul Goldschmidt vs. Cody Bellinger: Who plays 1B in 2026?Spencer Jones and George Lombard Jr. minor league updatesShould Aaron Judge eventually move to first base?Debate: Is A-Rod the best 3B in Yankee history?Shout-out to Cozzini's extended familyYankees Trivia

US equity markets resumed trading following the Juneteenth National Independence Day holiday, with investors' attention remaining keenly focussed on developments in the Middle East - Dow inched +35-points or +0.08% higher. Apple Inc rose +2.25% to be the leading performer in the 30-stock index and buck a weaker trend among the so-called ‘Magnificent Seven', with reports emerging executives have held internal talks about potentially bidding for artificial intelligence (AI) startup Perplexity AI. If regulators order Apple to end its partnership with Google, purchasing Perplexity would make it easier for the company to develop an AI-based search engine. The Bloomberg report came after CNBC confirmed on Friday (20 June) that Meta Platforms Inc (down -1.93%) approached Perplexity AI about a potential takeover bid before ultimately investing $14.3B into Scale AI. Microsoft Corp eased -0.59% to US$477.40 after touching a fresh record intra-day high (US$483.46). Amazon.com Inc lost -1.33% after the news that the UK's Groceries Code Adjudicator has opened a formal investigation over concerns that the retail giant may have breached rules requiring timely payments to suppliers.

The Nats lost on Friday night 6-5 at Dodger Stadium to open their nine game West Coast Road Trip. Mark (From LA) & Al discuss MacKenzie's Gore subpar's outing where he gave up five earned runs in over five innings of work. Gore issued four walks and only recorded four strikeouts, keeping him behind Boston Garrett Crochet for the MLB lead in strikeouts.(09:45) The offense slugged a trio of homers but was only 1 for 8 w/ RISP. Riley Adams ended an 0 for 32 slump in emphatic fashion with a solo HR in the top of the 5th to cut the deficit to 4-2.(18:00) Luis Garcia Jr. had a clutch pinch-hit 2-run double to trim the Dodger lead to 6-4 in the top of the 7th.  Amed Rosario got the nod at 2B (and homered) and Garcia replaced Andres Chapparo at DH for the pinch- hit opportunity.(21:10) Paul DeJong had four hits on Friday night in his rehab assignment with AA-Harrisburg. It is looking like DeJong will serve as an utility infielder for Washington as Brady House is now occupying 3B.(23:40) A quick look at what we know about the contractual situations for both the Manager and GM. 

Reading by Kara Cripps ---   1 Kings 10-11; 2 Chronicles 9   https://www.biblegateway.com/passage/?search=1%20Kings%2010-11%3B%202%20Chronicles%209&version=ESV&interface=print

Send us a textWhat happens when you sell your thriving Amazon brand to a $3B aggregator... and then watch them destroy everything you built?That's exactly what happened to Ben Leonard, the founder of Beast Gear—a strength and conditioning brand that became Thrasio's first European acquisition. But here's the twist: Ben got the brand back. And now, he's sharing the *entire resurrection journey in public.In this no-BS episode of **eCommerce OS Fast Track**, we break down:The inside story of selling to Thrasio and what really went downThe operational chaos that led to the brand's collapseWhy most Amazon aggregators failed (and what founders can learn)How Ben is rebuilding the brand with radical transparencyTactical moves for DTC revival, email capture, content, and CXWhat *NOT* to do when scaling through acquisitionWhether you're building a $1M brand or eyeing an 8-figure exit, this is essential viewing. Ben's story is a cautionary tale, a comeback playbook, and a masterclass in eCommerce brand-building rolled into one.Hit the bell to follow the full turnaround in real time.

 A source confirming to CNBC that  Meta tried to buy Perplexity before the $14.3B deal for Scale AI and its founder Alexandr Wang. Plus, we look at Softbank's Masayoshi Son is continuing his trend of moonshot bets with a reported proposal to build a $1T AI hub in Arizona. 

Welcome to Omni Talk's Retail Daily Minute, sponsored by Retail Club and Mirakl. In today's Retail Daily Minute:Amazon CEO Andy Jassy outlines an AI-first future, with generative and agentic tools set to transform operations, streamline logistics, and reduce corporate headcount.TikTok Shop launches “Deals for You Days”, a two-week event packed with 50% discounts, livestream price guarantees, and continued e-commerce momentum—even as political scrutiny lingers.Live commerce platform Whatnot surges to $3B in sales, fueled by auction-style livestreams, strong community engagement, and rapid expansion into new categories like fashion and electronics.The Retail Daily Minute has been rocketing up the Feedspot charts, so stay informed with Omni Talk's Retail Daily Minute, your source for the latest and most important retail insights. Be careful out there!

Go to https://surfshark.com/elev8 and use code elev8 at checkout to get 4 extra months of Surfshark VPN!Doug Ford raises eyebrows with a push for armed citizens, while Mark Carney faces backlash for sending $4.3B abroad—this time to Ukraine, after major jobs cuts in Canada. Canadians question priorities as outrage grows.Send a one-time contribution to the show - https://www.paypal.com/donate/?hosted_button_id=XARF5X38AMZULListen to our Podcast on the go: https://podcasters.spotify.com/pod/show/elev8podcastTikTok: https://www.tiktok.com/@elev8podcast X: https://twitter.com/TheElev8Podcast

Today's Headlines: Missile strikes between Israel and Iran have continued for six days, with President Trump escalating tensions online by demanding Iran's “unconditional surrender” and revealing the U.S. knows the ayatollah's location. Amid warnings from global powers and regional evacuations, Trump faces pushback at home, including a bipartisan congressional resolution requiring approval for U.S. involvement. Meanwhile in New York, Democratic mayoral candidate Brad Lander was arrested by ICE during a volunteer shift, prompting outrage, as Trump calls for more deportations in Democratic cities—despite his administration reversing course multiple times on where raids should occur. Elsewhere, Elon Musk's AI startup is reportedly seeking $4.3 billion in new funding after burning through its previous rounds, and Senate Republicans are proposing to sell 3.3 million acres of federal land in 11 Western states to raise revenue. Resources/Articles mentioned in this episode: CNN: June 17, 2025 – Israel-Iran conflict  Axios: Congress dodges preemptive confrontation with Trump over Iran  NYT: Brad Lander, NYC Mayoral Candidate, Arrested by ICE Agents at Immigration Courthouse Axios: Trump orders ICE to hit Democrat-run cities with deportation blitz  WaPo: Trump officials reverse guidance exempting farms, hotels from immigration raids  CBS News: DHS Secretary Kristi Noem brought to hospital due to allergic reaction  Bloomberg: Elon Musk's xAI in Talks to Raise $4.3B in Equity Funding WAPo: Senate GOP plan would sell millions of acres of Western public land Morning Announcements is produced by Sami Sage and edited by Grace Hernandez-Johnson Learn more about your ad choices. Visit megaphone.fm/adchoices

不再裝乖，你的期待與我無關：從邊緣人到大學教授，ChaCha的勇闖美利堅 Instagram: whatsupchacha 博客來：https://www.books.com.tw/products/0011023280 誠品線上：https://www.eslite.com/product/10012010042682919905003 誠品書店松菸｜《不再裝乖，你的期待與我無關》新書分享會 活動期間 2025年6月29日 14:00-15:00 活動地點 誠品生活松菸，3F 書店 FORUM 6/29（日）14:00-15:00│松菸店 3F FORUM 活動頁面：https://meet.eslite.com/tw/tc%3B/artshow/202505280062 主講│ChaCha（本書作者） 總覺得自己和別人不同，格格不入嗎？一直裝乖很累，活得很憋屈嗎？你的痛苦ChaCha都懂，本書就是你的救贖！這本書不是什麼心靈雞湯，也不是成功手冊，但它有著ChaCha這30多年來最真實的邊緣人生。看ChaCha如何勇闖美利堅，用獨特的Cha式幽默化解危機，翻轉劇情，改寫不一樣的人生劇本！ 主辦單位│聯經出版 參加方式│自由入場，座位有限，額滿為止。 聯絡電話│02-8692-5588 轉5345 備註說明│如活動因氣候或其他因素暫停或變動，請依現場公告為準。 -- Hosting provided by SoundOn

The Nats losing streak extended to nine games on Monday night as victory slipped through their fingertips in the 6-4 defeat. Mark & Al begin with Kyle Finnegan, who inherited a one run lead in the top of the 9th, but allowed a pair of Rockies homers, the only home runs he has given up this season.(09:00) Brady House went 0 for 3 with a walk in his MLB debut.  House was the #11 overall pick in the 2021 Draft and had a OPS of .872 this season thus far in AAA-Rochester. House looked comfortable defensively and Davey Martinez said pregame that House will be the everyday 3B.(14:40) Daylen Lile hit his first career MLB homer in the bottom of the 5th in his first game since returning from AAA. Lile swapped roster spots with Robert Hassell III after Sunday's defeat.(18:00) James Wood's 2-run HR in the bottom of the 5th put Washington ahead 4-3 until the fateful 9th inning. Wood is now up 18 homers on the season; which is tied for 5th most in the NL.(20:15) Riley Adams got the nod at catcher and is now 0 for his last 30 at the plate. His OPS is down to a paltry .325 and the catching situation continues to worsen for the franchise.(23:15) Jake Irvin gave up a 2-run HR in the top of the 1st and his opening frame ERA is a shocking 10.84; surprisingly more than his Mitchell Parker. Irvin ended his evening with six innings of work off of five hits.(27:15) A discussion on recent Washington Post stories covering the angst within the franchise during this brutal stretch.(36:30) A Nats Chat Flashback from July 19th, 2023 when Brady House was promoted to AA-Harrisburg after a brief stay at High-A Wilmington. 

Reading by Robyn Byus ---   1 Kings 9; 2 Chronicles 8   https://www.biblegateway.com/passage/?search=1%20Kings%209%3B%202%20Chronicles%208&version=ESV&interface=print

Chris Degnan is one of the most legendary CROs of this generation. He joined Snowflake as employee #13 and the 1st sales hire. He scaled the sales org from 0 to over $3B in ARR, spanned four CEOs, and retired as CRO after 11 years. In his first podcast post-retirement, Chris opened his CRO playbook, from early enablement to hiring rigor and fending off threats from competitors. He also reflects on lessons from working with leaders like Frank Slootman, John McMahon, and Sridhar Ramaswamy. If you're a founder or running sales at a startup, this one is for you. (00:00) Introduction to Chris's Journey at Snowflake (01:47) Navigating Leadership Changes (04:39) The Importance of Sales Methodology and Enablement (10:22) Near-Death Experiences and Company Resilience (13:39) Building a Strong Sales Organization (27:25) Hiring and Scaling the Sales Team (34:52) Board Dynamics and Mentorship (44:29) The Influence of John McMahon (46:22) Leadership Styles and Intuition (46:56) Launching Snowflake Japan (49:39) Learning from Leaders (55:10) The Importance of Competitive Moats (59:12) Snowflake vs. Databricks (01:07:45) Public vs. Private Markets (01:14:03) Sales and Marketing Synergy (01:26:17) Final Thoughts and Future Plans Executive Producer: Rashad Assir Producer: Leah Clapper Mixing and editing: Justin Hrabovsky Check out Unsupervised Learning, Redpoint's AI Podcast: https://www.youtube.com/@UCUl-s_Vp-Kkk_XVyDylNwLA

Reading by Kara Cripps ---   1 Kings 8; 2 Chronicles 5   https://www.biblegateway.com/passage/?search=1Kings%208%3B%202%20Chronicles%205&version=ESV&interface=print

Prosper Trading Academy's Scott Bauer says Meta Platforms (META) is a stock to "buy the dip" on any pullback, saying it continues to build its position in A.I. META announced a $14.3B investment into Scale AI as Mark Zuckerberg aims to create a superintelligence lab. Later, Scott creates an example options trade for META using a July 18th strike date and a bullish call spread strategy. Scott adds commentary on Apple (AAPL) on reports that the long-awaited Siri update is delayed until spring 2026.======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

Meta making its investment in scale AI official. Spending $14.3B for a 49% stake in the company, as CEO Alexandr Wang departs for a role inside Meta. We dig into how tech giants are spending

Send us a text00:00 - Intro00:51 - Scale AI gets $14.3B from Meta, hits $29B valuation02:03 - Starlink doubles subs to 6M, adds 100K in Africa03:22 - SpaceX expands Starship launch capacity in Florida04:08 - Databricks adds Google Gemini, hits $72.8B valuation05:09 - Perplexity partners with Nvidia, eyes $14B raise06:08 - Glean raises $150M at $7.2B valuation07:13 - Mistral hits $6B valuation, expands sovereign AI reach08:32 - Gecko Robotics doubles to $1.25B valuation09:28 - Bullish files confidentially for US IPO

In this Father's Day episode, we explore the Northwest sector in Feng Shui and its connection to father energy, leadership, and protection. We also look at how the father wound can show up in our lives and how to begin healing. In our Folklore Friday segment, we dive into men's vitality in Chinese medicine—touching on jing, semén retention, and how ancient practices supported masculine energy over time.-------------00:00 intro00:28 welcome 01:43 Northwest sector 08:33 Father wounds 12:16 Feng Shui adjustments to encourage leadership 14:59 TCM and Male vitality 22:15 Final Thoughts22:58 Outro ---------Free Floor plan mapping: ⁠learnfengshuinow@gmail.com⁠ OR https://www.learnfengshui.com/freemappingConnect on social media & contact me HERE ⁠https://linktr.ee/learnfengshuinow⁠:---------Sources: Jing- https://rebelmednw.com/2020/07/traditional-chinese-medicine-and-mens-health/https://www.fusionhealth.com.au/blogs/featured-blogs/what-is-jing?srsltid=AfmBOoqh58AnlfWkRnzKgaMCrlX8Q6u62p0qhSIjBcSk9ZRgcqxGA3EP⁠https://en.wikipedia.org/wiki/Jing_(Chinese_medicine)#:~:text=Jing%20(Chinese%3A%20精%3B%20pinyin,Treasures%20of%20traditional%20Chinese%20medicine.⁠https://www.britishacupuncturefederation.co.uk/2023/01/03/the-three-treasures-jing-shen-and-qi/https://www.attachmentproject.com/psychology/father-wound/

Reading by Deborah Volosin ---   1 Kings 7; 2 Chronicles 4   https://www.biblegateway.com/passage/?search=1%20Kings%207%3B%202%20Chronicles%204&version=ESV&interface=print

With freshwater becoming more and more limited, our planet turns its sights to decentralized water solutions. Brian Sheng, Co-Founder and CEO of Aquaria, has developed a technology to capture the vapor in the air and turn it into liquid water. Joining Corinna Bellizzi, he shares how their Atmospheric Water Generator (AWG) does its wonders to make clean water more accessible to all, from disaster relief efforts to residential homes. Brian also discusses the proper way to install, maintain, and power an AWG to maximize its output and potential.About Guest:Brian Sheng is the Co-Founder and CEO of Aquaria, building air-water infrastructure to produce scalable water systems that create clean drinking water from the air. Aquaria's mission is to safeguard and unlock global access to clean water. As a serial entrepreneur, Brian co-founded The Vanguard, Fresh VC, and he founded Asia Horizon. Additionally he served as a General Partner at The Arcview Group. Brian's seed stage portfolio is valued at over $3B with 2 IPOs, Fiscalnote and Clever Leaves. While attending Princeton University, Brian wrote his thesis on atmospheric water generation. Brian was honored as a member of Forbes 30 under 30 class of 2024, and Aquaria was named one of TIME's Best Inventions of 2024.Guest LinkedIn: https://www.linkedin.com/in/brian-sheng/Guest Website: https://aquaria.world/Guest Social: https://www.linkedin.com/company/aquariaawg/https://www.instagram.com/aquariaawgShow Notes: Raw audio00:02:35 - Brian Sheng Of Aquaria00:06:19 - How Atmospheric Water Generator Works00:12:03 - Using Air Water To Put Out Forest Fires00:14:35 - AGW Infrastructure And Energy Requirements00:19:10 - How It Compares To Municipal Water00:21:21 - Installing AGW For Home Use00:30:08 - Lessons From The Private And Public Sectors00:34:54 - Aquaria's Pursuit For A Better World00:37:06 - Becoming A Public Benefit Corporation00:41:30 - Encouraging Potential Competitors00:46:23 - Proper Maintenance Of AGW Unit00:47:46 - Pushing Forward And Legacy Building00:49:56 - Creating More Things Out Of Thin Air00:51:24 - Keeping An Optimistic And Hopeful Vision00:52:27 - Episode Wrap-up And Closing WordsJOIN OUR CIRCLE. BUILD A GREENER FUTURE:

Reading by David Anderson ---   1 Kings 5-6; 2 Chronicles 2-3   https://www.biblegateway.com/passage/?search=1%20Kings%205-6%3B%202%20Chronicles%202-3&version=ESV&interface=print

In this conversation from 2024, Alex speaks with Marc-William Palen about the evolution of left-wing visions of free trade from the mid-19th century through the Cold War, highlighting key movements and figures like the Anti-Corn Law League, Karl Marx, and the Fair Trade movement, and contrasting these with protectionist and imperialist policies of the era. Episode Notes: Marc-William's book "Pax Economica: Left-Wing Visions of a Free Trade World": https://press.princeton.edu/books/hardcover/9780691199320/pax-economica  Marx on Free Trade: https://www.marxists.org/archive/marx/works/1888/free-trade/#:~:text=Only%20under%20Free%20Trade%20can,%2C%20wage%2Dlaborers%20there%3B%20hereditary  The Eric Schliesser episode of the Curious Task mentioned by Alex: https://thecurioustask.podbean.com/e/special-episode-5-eric-schliesser-%e2%80%94-what-is-neoliberalism/  Journal of Liberal History's summary of the history of the Anti-Corn Law League: https://liberalhistory.org.uk/history/anti-corn-law-league/  Overview of the history of the Opium Wars: https://asiapacificcurriculum.ca/learning-module/opium-wars-china#:~:text=The%20Opium%20Wars%20in%20the,China%20lost%20both%20wars.  A primer on the origins of Fair Trade and the Haslemere Declaration:  https://imperialglobalexeter.com/2018/05/03/what-fair-trade-was-originally-about-the-haslemere-declaration-of-1968/ 

In this episode of the SHIFT podcast, Blake Mallen interviews Rob Sperry, a seasoned leader in the direct selling industry. Rob's journey from skepticism to remarkable success provides valuable insights for direct sales leaders seeking sustained success. Rob Sperry has coached the best of the best—and seen what works (and what fails) in every corner of the channel. This is a can't-miss episode for anyone who wants to strengthen culture, drive results and bridge the gap between leadership potential and lasting performance In this episode, you will learn: Why most leaders plateau—and how to break through How to identify and avoid the “Weapons of Mass Distraction” stealing your momentum The power of personal branding to elevate your presence and influence A DSN PRODUCTION The SHIFT podcast is presented by Direct Selling News (DSN), the most trusted media source in the direct selling channel for over two decades. From supporting executive communities from more than 1,000 companies, over 200 issues of Direct Selling News magazine and our annual Global 100 list we've consistently delivered professional reporting on vital industry news, trends, highlights, and insights. Now, for the first time, we're extending this level of insight and credibility directly to YOU! The most important and powerful Distributor community across the globe! MEET YOUR HOST BLAKE MALLEN, a billion-dollar brand builder and community marketing expert, is the perfect person to bring this content to life. With 25+ years of field, ownership, and executive experience generating $3B+ in revenue, Blake brings a fresh and unique perspective from across the direct selling industry. He is passionate about the power of potential and works with companies and communities to make the shifts needed to discover and develop theirs.

Petie talks about growing up a Dodgers fan, his favorite players and mentors, and filling in as 3B coach during a recent homestand. 

10,000 people retire every day. Are you ready to buy your time back?   On this

You're one mentor away from a multimillion-dollar breakthrough.   Vinney Chopra started with just $1,000… and built a $1.3B real estate empire.   In this powerful episode of The Abundance Mindset, he and Gualter Amarelo unpack the game-changing power of mentorship. Vinney shares how borrowing money to join masterminds and invest in the right mentors—like syndication legend Dave Lindahl—compressed decades into years.   Whether you're broke, scared, or skeptical, one truth stands: you can't afford NOT to have a mentor.  

Send us a textIt's another beautifully chaotic episode of the Ones Ready Daily Drop, and today we're launching straight into the bureaucratic bonfire. Jared's back with updates so wild you'd think the Pentagon was drunk texting Congress. From billion-dollar GPS launches to PFAS exposure going prime time, we're diving headfirst into drone dread, six-gen fighter delays, Space Force spending black holes, and the VA disability floodgates cracking wide open.Also: A WWII hero finally gets his due, Canada's prepping for WWIII by 2028, and NATO's still hoping its members hit 2% defense spending...by 2036. Meanwhile, GPS going dark could cause global chaos (shocker), and everyone's pretending we'll somehow counter Ukraine-style drone strikes with... what, PowerPoints?

A chaotic day leads Don into a deep (and entertaining) dive into the futility of market timing, spurred by a recent Morningstar article on Pacer's Trendpilot ETF. Don and Tom break down the mechanics of the fund's strategy, its underperformance compared to a simple 60/40 portfolio, and the long-term cost of trying to avoid downturns. Listener questions bring up diversification, Roth IRAs, and the eternal struggle with ticker symbols. Plus, a special heads-up for federal employees about an upcoming webinar. And yes, kilt ventilation is discussed. 0:04 “It never rains but it pours” rant, helicopters, kilts, and chaos 2:02 Welcome and the evolution from market timing believers to skeptics 3:13 Trendpilot ETF's moving average strategy explained (kind of) 5:45 Morningstar says: strategy failed, underperformed S&P by 5% annually 6:58 97-year 60/40 portfolio beats Trendpilot in return and volatility 8:32 2020 example: Trendpilot missed the 38% rebound—ouch 9:59 Why market timing fails most investors over time 11:05 Loss aversion vs. long-term strategy with fixed income 13:08 Trendpilot's $3.3B in AUM—but it still doesn't justify market timing 14:23 Listener mail: VTEB vs VTBE, Series 65 textbook gems, diversification 18:26 How much in a single stock? Almost none 19:10 Roth IRA allocation question—AVUS, DFIV, AVUV, and maybe just AVGE 22:24 One-fund to rule them all: AVGE breaks it down across 15 funds 24:11 Federal employee webinar pitch – June 7 at appellowealth.com 25:39 Wrapping up with call-in info, dreams about forgetting the phone number, and kilts (again) Learn more about your ad choices. Visit megaphone.fm/adchoices

Ben Maller talks about Red Sox OF Jaren Duran saying that leading the league in 1-run losses shows they are a really good team, the Atlanta Braves adding Freddie Gonzalez as their 3B coach, Trevor Bauer winning a settlement against his accuser, Too Much or Not Enough, #QueenOfHearts w/ LaReina, and more!See omnystudio.com/listener for privacy information.

Today's show: Alex and Lon discuss Windsurf getting abruptly cut off from Anthropic just before a rumored $3B acquisition by OpenAI, sparking questions around platform risk and foundation-model politics; Deel defends itself by arguing the information it allegedly took was public or obvious, complicating its ongoing legal saga; and Flock Safety's neighborhood-focused surveillance tech—combining LPR cameras and drones—positions itself as a privacy-conscious tool that gives elected officials control over community data governance.Timestamps:(0:00) Episode Teaser(2:48) ADP's Employment Numbers Might Make Your Eyes Water(5:54) Is the Circle IPO Over Subscribed?(9:25) Vanta - Get $1000 off your SOC 2 at https://www.vanta.com/twist(13:00) Anthropic Shows Sharp Elbows With Windsurf(19:55) Lemon.io - Get 15% off your first 4 weeks of developer time at https://Lemon.io/twist(20:57) Is It Really Stealing If It's Public or Obvious? Deel Says No(29:23) Northwest Registered Agent. Form your entire business identity in just 10 clicks and 10 minutes. Get more privacy, more options, and more done—visit northwestregisteredagent.com/twist today!(30:50) The Space Future Alex Has Dreamed About(35:10) Anthropic Can't Stop Scraping Reddit's Data(42:44) Flock Safety is Bringing Surveillance To a Neighborhood Near YouSubscribe to the TWiST500 newsletter: https://ticker.thisweekinstartups.comCheck out the TWIST500: https://www.twist500.comSubscribe to This Week in Startups on Apple: https://rb.gy/v19fcpLinks from episode:Impulse Space: https://www.impulsespace.com/Flock Safety: https://www.flocksafety.com/Follow Garrett:X: https://x.com/glangleyLinkedIn: https://www.linkedin.com/in/glangley/Follow Lon:X: https://x.com/lonsFollow Alex:X: https://x.com/alexLinkedIn: ⁠https://www.linkedin.com/in/alexwilhelmFollow Jason:X: https://twitter.com/JasonLinkedIn: https://www.linkedin.com/in/jasoncalacanisThank you to our partners:(9:25) Vanta - Get $1000 off your SOC 2 at https://www.vanta.com/twist(19:55) Lemon.io - Get 15% off your first 4 weeks of developer time at https://Lemon.io/twist(29:23) Northwest Registered Agent. Form your entire business identity in just 10 clicks and 10 minutes. Get more privacy, more options, and more done—visit northwestregisteredagent.com/twist today!Great TWIST interviews: Will Guidara, Eoghan McCabe, Steve Huffman, Brian Chesky, Bob Moesta, Aaron Levie, Sophia Amoruso, Reid Hoffman, Frank Slootman, Billy McFarlandCheck out Jason's suite of newsletters: https://substack.com/@calacanisFollow TWiST:Twitter: https://twitter.com/TWiStartupsYouTube: https://www.youtube.com/thisweekinInstagram: https://www.instagram.com/thisweekinstartupsTikTok: https://www.tiktok.com/@thisweekinstartupsSubstack: https://twistartups.substack.comSubscribe to the Founder University Podcast: https://www.youtube.com/@founderuniversity1916

TimestampsEp 1692:45 - Our head-t0-head heroes starts with a discussion on Jeremy Pena's breakout season.13:33 - Pete's Hero, Zack Littell, is an interesting example of player whose value is based on format as much as anything.21:05 - Is James Wood a top 20 player moving forward?31:00 - Are we just as high on PCA?39:30- How should we view Kyle Stowers and Andy Pages - and who do we like more?52:48- Taking a look at 3B where Alex Bregman and Junior Caminero are - for the moment - trending opposite directions but maybe landing in the same place.Subscribe: Apple Podcasts | Spotify | Stitcher | TuneIn | Google Podcasts | RSSConnect: Twitter | keeporkut@gmail.com | Join PL+Get PL+ and join our Discord: https://pitcherlist.com/plus Join Our Discord & Support The Show: PL+ | PL Pro - Get 15% off Yearly with code PODCASTProud member of the Pitcher List Fantasy Baseball Podcast Network

TimestampsEp 1692:45 - Our head-t0-head heroes starts with a discussion on Jeremy Pena's breakout season.13:33 - Pete's Hero, Zack Littell, is an interesting example of player whose value is based on format as much as anything.21:05 - Is James Wood a top 20 player moving forward?31:00 - Are we just as high on PCA?39:30- How should we view Kyle Stowers and Andy Pages - and who do we like more?52:48- Taking a look at 3B where Alex Bregman and Junior Caminero are - for the moment - trending opposite directions but maybe landing in the same place.Subscribe: Apple Podcasts | Spotify | Stitcher | TuneIn | Google Podcasts | RSSConnect: Twitter | keeporkut@gmail.com | Join PL+Get PL+ and join our Discord: https://pitcherlist.com/plus Join Our Discord & Support The Show: PL+ | PL Pro - Get 15% off Yearly with code PODCASTProud member of the Pitcher List Fantasy Baseball Podcast Network

TimestampsEp 1692:45 - Our head-t0-head heroes starts with a discussion on Jeremy Pena's breakout season.13:33 - Pete's Hero, Zack Littell, is an interesting example of player whose value is based on format as much as anything.21:05 - Is James Wood a top 20 player moving forward?31:00 - Are we just as high on PCA?39:30- How should we view Kyle Stowers and Andy Pages - and who do we like more?52:48- Taking a look at 3B where Alex Bregman and Junior Caminero are - for the moment - trending opposite directions but maybe landing in the same place.Subscribe: Apple Podcasts | Spotify | Stitcher | TuneIn | Google Podcasts | RSSConnect: Twitter | keeporkut@gmail.com | Join PL+Get PL+ and join our Discord: https://pitcherlist.com/plus

In today's episode, we weave together Trump's idea to spend $3B on trade schools, ending student visas to Chinese and Indian nationals, and the boldness and urgency of Phil Robertson's gospel message to President Trump. Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's episode, we weave together Trump's idea to spend $3B on trade schools, ending student visas to Chinese and Indian nationals, and the boldness and urgency of Phil Robertson's gospel message to President Trump. Learn more about your ad choices. Visit megaphone.fm/adchoices

Paul and Justin discuss the Top 5s at SS and 3B along with some notable disappointments and other key players Source

(00:00) Zolak and Holley kick off the last hour by discussing Alex Cora’s comments on Rafael Devers not playing 3B. (15:18) The crew touches on Trevor Story and what the Red Sox should do with him. (21:54) The guys wrap-up the day by reacting to Channing Crowder and his comments made on Bill Belichick and Jordon Hudson. (35:28) Today’s Takeaways.